AngioDynamics, Inc. (NASDAQ:ANGO) has received a consensus recommendation of “Buy” from the eleven analysts that are currently covering the firm, Marketbeat Ratings reports. Five research analysts have rated the stock with a hold rating, four have assigned a buy rating and one has assigned a strong buy rating to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $17.58.
Several research analysts have issued reports on the company. BidaskClub upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research note on Friday, March 30th. Zacks Investment Research lowered AngioDynamics from a “buy” rating to a “hold” rating in a research note on Friday, January 26th. ValuEngine upgraded AngioDynamics from a “hold” rating to a “buy” rating in a research note on Friday, April 6th. TheStreet lowered AngioDynamics from a “b-” rating to a “c” rating in a research note on Tuesday, January 2nd. Finally, Canaccord Genuity increased their price objective on AngioDynamics from $16.50 to $17.00 and gave the stock a “hold” rating in a research note on Monday, April 2nd.
Several large investors have recently made changes to their positions in the company. BlackRock Inc. increased its stake in shares of AngioDynamics by 1.7% in the fourth quarter. BlackRock Inc. now owns 4,730,396 shares of the medical instruments supplier’s stock valued at $78,666,000 after buying an additional 76,859 shares in the last quarter. Janus Henderson Group PLC increased its stake in shares of AngioDynamics by 49.4% in the third quarter. Janus Henderson Group PLC now owns 1,439,873 shares of the medical instruments supplier’s stock valued at $24,607,000 after buying an additional 476,327 shares in the last quarter. Wells Fargo & Company MN increased its stake in shares of AngioDynamics by 11.0% in the fourth quarter. Wells Fargo & Company MN now owns 1,138,161 shares of the medical instruments supplier’s stock valued at $18,928,000 after buying an additional 112,928 shares in the last quarter. Royce & Associates LP increased its stake in shares of AngioDynamics by 13.8% in the fourth quarter. Royce & Associates LP now owns 1,098,817 shares of the medical instruments supplier’s stock valued at $18,273,000 after buying an additional 133,660 shares in the last quarter. Finally, Fenimore Asset Management Inc. increased its stake in shares of AngioDynamics by 0.6% in the fourth quarter. Fenimore Asset Management Inc. now owns 594,490 shares of the medical instruments supplier’s stock valued at $9,886,000 after buying an additional 3,715 shares in the last quarter. Institutional investors own 95.43% of the company’s stock.
AngioDynamics stock remained flat at $$19.90 during mid-day trading on Thursday. The company’s stock had a trading volume of 12,763 shares, compared to its average volume of 264,833. The company has a quick ratio of 1.84, a current ratio of 2.88 and a debt-to-equity ratio of 0.16. AngioDynamics has a 1 year low of $14.80 and a 1 year high of $20.71. The firm has a market capitalization of $734.99, a price-to-earnings ratio of 27.74, a P/E/G ratio of 1.80 and a beta of 1.00.
AngioDynamics (NASDAQ:ANGO) last released its quarterly earnings data on Thursday, March 29th. The medical instruments supplier reported $0.25 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.20 by $0.05. AngioDynamics had a return on equity of 5.11% and a net margin of 0.97%. The firm had revenue of $83.85 million during the quarter, compared to analyst estimates of $86.13 million. sell-side analysts forecast that AngioDynamics will post 0.74 EPS for the current fiscal year.
ILLEGAL ACTIVITY NOTICE: “AngioDynamics, Inc. (ANGO) Receives Consensus Rating of “Buy” from Brokerages” was originally reported by The Ledger Gazette and is the sole property of of The Ledger Gazette. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of U.S. & international copyright and trademark legislation. The original version of this piece can be read at https://ledgergazette.com/2018/05/17/angiodynamics-inc-ango-receives-consensus-rating-of-buy-from-brokerages.html.
AngioDynamics Company Profile
AngioDynamics, Inc designs, manufactures, and sells various medical, surgical, and diagnostic devices for the treatment of peripheral vascular disease, vascular access, and for use in oncology and surgical settings in the United States and internationally. The company provides manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; VenaCure EVLT laser system products to treat superficial venous diseases; Asclera drug for treating uncomplicated spider and reticular veins of the lower extremities; and Sotradecol drugs for treating small uncomplicated varicose veins of the lower extremities.
Receive News & Ratings for AngioDynamics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AngioDynamics and related companies with MarketBeat.com's FREE daily email newsletter.